●Q3 Revenue of $8.8 million ●Q3 Cash Collections of $10.0 million ●Q3 Thyroid test volume up 12% year-over-year to record levels ●Q3 Thyroid revenue of $8.8M; up 22% year-over-year to record levels    PARSIPPANY, NJ, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the third quarter ended September 30, 2025 and provided a business and financial update. Third quarter Net Revenue was $8.8 million. Income from cont ...

Core Insights - The collaboration between Oracle Health and Life Sciences and the Cancer Center Informatics Society (Ci4CC) aims to advance AI innovation in oncology care and research [1][2] - The partnership will focus on designing an EHR optimized for cancer care, integrating clinical and genomic data for personalized medicine, and pioneering AI-driven approaches for clinical trial innovation [2][3] Collaboration Details - The strategic collaboration combines Oracle's technology with Ci4CC's national network of NCI-Designated and Community Care Cancer Centers [2] - The initiative will include establishing robust real-world evidence frameworks and advancing precision oncology platforms [2][4] Leadership Statements - Seema Verma from Oracle emphasized the potential of AI and data science in combating cancer, highlighting the opportunity to accelerate discoveries [2] - Sorena Nadaf-Rahrov from Ci4CC noted that advancements in cancer research require collaborative networks, which is central to their mission [3][4] Operational Goals - The collaboration aims to turn data into actionable knowledge to improve cancer research and patient care [4] - The agreement is non-binding, indicating a flexible approach to the partnership [4]

Core Insights - The report "Biomarker Deals: Terms Value and Trends 2019-2025" indicates a shift in investment priorities and an increase in biomarker innovation through partnerships to enhance development and market reach [1][2] Market Dynamics - The global biomarkers industry is experiencing a surge in strategic transactions, including licensing, acquisitions, and collaborations, with various deal structures such as upfront payments and milestone-based compensation [2] - The demand for precision medicine, early disease detection, and targeted therapies is driving new biomarker-related partnerships and acquisitions [3] Growth Drivers - The rising incidence of chronic and infectious diseases, such as cancer and diabetes, is increasing the need for early diagnosis and effective treatment, thereby driving demand for biomarkers [4] - Advances in omics and imaging technologies are revolutionizing biomarker discovery and validation, making development more efficient and precise [5] - The shift towards personalized medicine is increasing the need for reliable biomarkers, leading to more partnerships and licensing deals focused on targeted diagnostics and therapies [6] Market Segmentation - The report segments the market based on deal type, including licensing, acquisitions, and collaborations, with partnerships expected to dominate through 2025 [13][14] Challenges and Opportunities - Key challenges in the biomarkers market include high development costs and the need for skilled labor, while opportunities lie in emerging markets and the growth of personalized medicine [15] Emerging Startups - Notable emerging startups in the biomarker space include Grail, Nucleix, Biodesix, and SomaLogic [10][19] Market Leaders - Major players in the biomarkers industry include Abbott, Agilent Technologies, Bayer AG, and Thermo Fisher Scientific, among others [20]

Core Insights - Laboratory Corp reported third-quarter 2025 adjusted earnings per share of $4.18, an increase from $3.50 a year ago, surpassing the consensus of $4.18 [1] - Sales rose 8.6% year-over-year to $3.56 billion, also beating the consensus of $3.56 billion [1] - The sales increase was attributed to organic revenue growth of 6.2%, acquisitions net of divestitures at 1.7%, and foreign currency translation contributing 0.7% [1] Financial Performance - Adjusted operating income for the quarter was $396.6 million, representing 11.1% of revenue [1] - The company revised its fiscal year 2025 adjusted earnings guidance from $16.05-$16.50 to $16.15-$16.50, compared to the consensus of $16.32 [3] - LabCorp lowered its 2025 sales guidance from $14.08 billion-$14.23 billion to $13.97 billion-$14.05 billion, against the consensus of $14.01 billion [3] Growth Projections - LabCorp forecasts 2025 sales growth of 7.4%-8%, down from prior guidance of 7.5%-8.6% [3] - The guidance includes Diagnostics Laboratories sales growth of 7.2%-7.8% and Biopharma Laboratory Services sales growth of 5.7%-7.1% [4] Market Position - Analyst Andrew F. Brackmann from William Blair reiterated an Outperform rating, noting LabCorp's steady organic growth in diagnostics and a solid M&A pipeline [4] - The company is positioned for long-term earnings growth, supported by a steady dividend and resilient valuation multiple [4] Stock Performance - Laboratory Corp's stock is down 5.23% at $261.25 as of the last check on Tuesday [5]

Core Insights - Oryzon Genomics has announced a strategic collaboration with Dr. Iman Barilero as Senior Advisor for Regulatory Affairs to advance its Phase III clinical program for vafidemstat in Borderline Personality Disorder (BPD) [1][4] Company Overview - Oryzon Genomics is a clinical-stage biopharmaceutical company founded in 2000 in Barcelona, Spain, and is a leader in epigenetics, focusing on personalized medicine for CNS disorders and oncology [5] - The company has a clinical portfolio that includes two LSD1 inhibitors: vafidemstat (Phase III-ready) and iadademstat (Phase II) [5] Regulatory Expertise - Dr. Iman Barilero brings over 30 years of global regulatory leadership experience, particularly in CNS, neuropsychiatry, and rare diseases, with a successful track record in guiding Phase II-III programs and securing global approvals [2][3] - Her previous role as Vice President at Lundbeck involved leading global regulatory strategies for breakthrough therapies targeting various CNS disorders [3] Clinical Development - Vafidemstat is currently being evaluated in a double-blind, randomized, placebo-controlled Phase IIb trial (EVOLUTION) for its potential to improve negative symptoms in schizophrenia [4][8] - The company is also preparing a clinical trial for vafidemstat in Autism Spectrum Disorder (ASD) and has conducted several Phase IIa trials with positive results in psychiatric disorders [8] Strategic Goals - The collaboration with Dr. Barilero aims to enhance regulatory dialogue with the FDA and provide strategic guidance across clinical development programs [7] - Oryzon's pipeline includes programs targeting schizophrenia and ASD, with a focus on advancing its late-stage pipeline in BPD and schizophrenia [4][8]

Future of Medicine & Personalized Healthcare - The future of medicine is shifting towards personalized approaches, recognizing the uniqueness of each individual's DNA and tailoring treatments accordingly [3][4] - Personalized medicine involves understanding an individual's genetic makeup to determine how their body might react to certain conditions, enabling targeted therapies with fewer side effects [4][5] - AI is being integrated into medicine to assist doctors in making faster and more accurate diagnoses by analyzing vast amounts of medical data, such as X-rays and MRI scans [6] - AI is also accelerating drug discovery by sifting through countless chemical compounds to identify potential candidates for specific diseases, reducing time and cost [7] - 3D bioprinting is emerging as a technology to repair or replace damaged body parts, with scientists experimenting with printing human tissues and simple organs [8] Technological Advancements & Opportunities - The completion of the Human Genome Project over 20 years ago laid the foundation for sequencing a person's DNA in days at a fraction of the cost [5][6] - The medical field is expanding and requires bioengineers, AI developers, data scientists, ethicists, artists, and communicators to contribute to the future of medicine [10][11] Impact on Global Health & Society - Advancements in medicine have the potential to prevent sickness before it starts through personalized nutrition, precise exercise plans, and early warnings from wearable devices [13] - The World Health Organization recognizes the potential of these advancements to completely change how we manage the global health crisis [13] - Future advancements could lead to treating or even eliminating diseases once deemed untreatable, stopping epidemics faster with AI tracking, and providing access to quality healthcare in remote areas through telemedicine [14] - A healthier society, stronger economy, and brighter future for humanity can be achieved through contributions to the future of medicine [15]

Core Insights - Hims & Hers Health, Inc. (HIMS) is transforming healthcare delivery through a vertically integrated, technology-driven model that combines telemedicine, data infrastructure, and AI-enabled personalization [1][7] - The company has made significant investments in AI, appointing Mo Elshenawy to lead the development of advanced healthcare algorithms and diagnostic tools, supported by an $870 million convertible notes offering [2][7] - Recent product innovations include a digitally managed hormone therapy program for men and AI-guided care personalization for women's hormonal health, positioning Hims & Hers as a leader in consumer-centric healthcare [3][7] Financial Performance - Hims & Hers shares have increased by 159.6% year-to-date, significantly outperforming the industry growth of 30.4% [6] - The Zacks Consensus Estimate for HIMS' 2025 earnings per share indicates a 122.2% improvement from 2024 [8] Valuation Metrics - HIMS' forward 12-month price-to-sales (P/S) ratio is 5.3X, which is lower than the industry's average of 5.9X but higher than its three-year median of 2.5X [10] - The company currently holds a Zacks Rank 4 (Sell) [12]

Core Insights - Phenom High Performance Medicine (Phenom HPM) is expanding its elite-level performance optimization services to a broader audience, including executives and fitness enthusiasts, previously reserved for professional athletes [1][11] - The clinic integrates naturopathic medicine with advanced sports science to address root causes of performance limitations rather than merely managing symptoms [3][5] Company Overview - Founded in 2013 by Dr. Callum Cowan and Dr. Nicola Kempinska, Phenom HPM is based in Burlington, Ontario [3][11] - The clinic's approach is proactive and personalized, focusing on comprehensive biomarker testing to identify hidden performance barriers [5][9] Methodology and Services - Phenom HPM employs a Performance Panel that examines various health markers, including micronutrients, hormone profiles, and gut health [5][6] - The clinic offers services such as IV nutrient therapy, hormone optimization, genetic profiling, and mental performance coaching, all supervised by board-certified naturopathic doctors [8][11] Evidence of Effectiveness - A case study highlighted a professional hockey player who, after targeted interventions, experienced significant improvements in energy and performance, including a 20% increase in point production [6][7] Healthcare Philosophy - Phenom HPM advocates for a shift from reactive to proactive healthcare, emphasizing optimization over symptom management [9][10] - The clinic aims to redefine healthcare through prevention and personalized medicine, showcasing the potential of the human body when performance barriers are removed [10][11]

Core Insights - Derek Maetzold, founder and CEO of Castle Biosciences, has been awarded CEO of the Year by The CEO Magazine, recognizing his impactful leadership and innovation in the diagnostics field [3][5]. Company Overview - Castle Biosciences, Inc. is a leading diagnostics company focused on improving health through innovative tests that guide patient care, with a mission to prioritize patients, clinicians, employees, and investors [6]. - The company has developed a portfolio of proprietary tests addressing critical challenges in skin cancers, Barrett's esophagus, and uveal melanoma, and is actively engaged in R&D for additional tests in high clinical need areas [7]. Leadership Recognition - Maetzold was selected as one of 10 finalists from a pool of 586 applicants for the Executive of the Year Awards, highlighting his visionary leadership and the company's growth from a startup to a recognized innovator in diagnostics [5]. - Under Maetzold's leadership, Castle has fostered a people-first culture, earning recognition as a Top Workplace USA for four consecutive years based on employee feedback [4].

Core Insights - STRATA Skin Sciences, Inc. has published a peer-reviewed study demonstrating the efficacy of its XTRAC 308nm Excimer Laser combined with 0.1% tacrolimus ointment for treating plaque-type psoriasis, showing significant improvement over topical monotherapy [1][2][3] Study Design and Findings - The study involved 100 adult patients with plaque-type psoriasis, divided into a control group receiving only tacrolimus and an observation group receiving both tacrolimus and Excimer laser therapy [3] - Key findings indicate that the observation group experienced a mean PASI reduction from 18.36 to 3.30, while the control group saw a reduction from 18.62 to 5.23, with a statistically significant difference (p < 0.01) [6] - The study highlights the safety profile, reporting no serious adverse events and only mild, self-resolving irritations in a few patients [6] Mechanism and Personalization - The combination therapy works through complementary immunomodulatory pathways, enhancing patient outcomes by targeting pathogenic T-cells and suppressing keratinocyte hyperproliferation [6] - Individualized dosing based on Minimum Erythema Dose (MED) allows for targeted treatment of lesions, maximizing benefits while minimizing exposure to healthy tissue [6] Strategic Implications - The study reinforces STRATA's leadership in personalized dermatologic care, supporting the use of Excimer laser in conjunction with topical agents and other therapies [5] - STRATA's President and CEO emphasized the importance of this study in advocating for expanded reimbursement from CMS, as demand for non-biologic treatment options grows [4] Company Overview - STRATA Skin Sciences is focused on developing innovative products for dermatologic conditions, including psoriasis, vitiligo, and acne, with offerings such as the XTRAC excimer laser and VTRAC lamp systems [7] - The company employs a unique Partnership Program to provide its technologies, which includes a fee per treatment cost structure and comprehensive support for practices [8]